Fátima Ferragut

ORCID: 0000-0001-9782-4804
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Galectins and Cancer Biology
  • Glycosylation and Glycoproteins Research
  • Signaling Pathways in Disease
  • Trypanosoma species research and implications
  • Research on Leishmaniasis Studies
  • Peptidase Inhibition and Analysis
  • Toxin Mechanisms and Immunotoxins
  • Insect symbiosis and bacterial influences
  • Advanced Thermodynamic Systems and Engines
  • Mast cells and histamine
  • Renin-Angiotensin System Studies
  • Congenital Anomalies and Fetal Surgery
  • Viral gastroenteritis research and epidemiology
  • Caveolin-1 and cellular processes
  • Synthesis and Biological Evaluation
  • Cancer, Hypoxia, and Metabolism
  • Receptor Mechanisms and Signaling
  • Cancer Cells and Metastasis

Consejo Nacional de Investigaciones Científicas y Técnicas
2014-2024

Experimental Medicine and Biology Institute
2021-2024

University of Buenos Aires
2014-2021

Instituto de Química y Fisicoquímica Biológicas
2014-2021

Institute of Astronomy and Space Physics
2019

National Agricultural Technology Institute
2016

Abstract T cells are central to the adaptive immune response against Trypanosoma cruzi infection. In chronic Chagas disease (CCD), circulating parasite-specific memory show reduced functionality and increased expression of inhibitory receptors as a result persistent antigenic stimulation. This phenotype has been linked progression cardiac pathology, whereas presence polyfunctional shows association with therapeutic success. this study, we demonstrate that T. cruzi–specific human CD4+ can be...

10.4049/jimmunol.2200436 article EN The Journal of Immunology 2023-01-04

Antigen-specific T cells are central to the adaptive immune response against T. cruzi infection and underpin efficacy of on-going vaccine strategies. In this context, present study focuses on T-cell assays that define parasite-specificity basis upregulation TCR stimulation-induced surface markers. For purpose, we tested different dual marker combinations (OX40, CD25, CD40L, CD137, CD69, PD-L1, CD11a, CD49d, HLA-DR, CD38) reliably identify activated CD4+ CD8+ populations from PBMCs chronic...

10.1111/imm.13622 article EN Immunology 2022-12-26
Coming Soon ...